Glaxo drug under fresh scrutiny
The US will today begin a review into GlaxoSmithKline’s diabetes drug Avandia. The Food and Drug Administration will debate over two days whether to restrict or withdraw the medicine, also known as rosiglitazone. Research in 2007 showed the drug could cause higher rates of heart attacks, while a government report earlier this year suggested the company may have been aware of the risks but did not withdraw the drug from sale.